Hartmut Döhner Selected Research

Nucleophosmin

1/2019	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
12/2017	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.
12/2017	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
7/2013	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
4/2013	Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays.
8/2012	Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
12/2011	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
8/2008	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
5/2008	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
3/2007	Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hartmut Döhner Research Topics

Disease

106	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 07/2003
60	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 08/2002
50	Neoplasms (Cancer) 01/2022 - 09/2002
41	Leukemia 01/2021 - 04/2002
11	Infections 01/2022 - 04/2005
11	Disease Progression 11/2020 - 11/2002
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 05/2006
8	Residual Neoplasm 01/2022 - 10/2004
7	Hematologic Neoplasms (Hematological Malignancy) 04/2020 - 04/2005
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2007 - 09/2002
6	Neutropenia 01/2022 - 04/2005
6	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2004
6	Acute Promyelocytic Leukemia 11/2019 - 02/2009
5	Multiple Myeloma 01/2022 - 07/2003
4	Lymphoma (Lymphomas) 02/2021 - 03/2003
4	Carcinogenesis 01/2017 - 01/2013
4	Melanoma (Melanoma, Malignant) 05/2013 - 09/2002
4	Hodgkin Disease (Hodgkin's Disease) 05/2012 - 04/2006
3	Febrile Neutropenia 01/2022 - 01/2020
3	Hemorrhage 01/2022 - 02/2009
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2009 - 09/2006
3	Lymphadenopathy 05/2008 - 08/2004
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2007 - 08/2004
3	Breast Neoplasms (Breast Cancer) 03/2007 - 09/2002
2	Thrombocytopenia (Thrombopenia) 11/2021 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 01/2013
2	Pathologic Complete Response 12/2020 - 12/2005
2	Trisomy (Trisomies) 01/2020 - 01/2004
2	Anemia 01/2016 - 02/2006
2	Fever (Fevers) 08/2014 - 04/2005
2	Hematologic Diseases (Blood Diseases) 06/2014 - 06/2013

Drug/Important Bio-Agent (IBA)

16	fludarabineIBA 01/2022 - 08/2004
15	Rituximab (Mabthera)FDA Link 01/2022 - 09/2011
15	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2005
15	AntigensIBA 01/2019 - 09/2002
14	Azacitidine (5 Azacytidine)FDA Link 10/2022 - 07/2015
11	NucleophosminIBA 01/2019 - 12/2005
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 02/2006
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2003
10	MicroRNAs (MicroRNA)IBA 01/2020 - 02/2011
10	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2020 - 01/2009
8	Core Binding Factors (Core-Binding Factor)IBA 12/2020 - 08/2007
7	midostaurinIBA 01/2022 - 01/2017
7	Messenger RNA (mRNA)IBA 04/2013 - 09/2002
6	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2021 - 03/2007
6	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2008
6	Biological ProductsIBA 01/2016 - 08/2002
5	venetoclaxIBA 10/2022 - 03/2014
5	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2013
5	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2005
5	Immunoglobulins (Immunoglobulin)IBA 11/2020 - 08/2002
4	Pharmaceutical PreparationsIBA 11/2021 - 03/2012
4	Decitabine FDA Link 01/2021 - 03/2012
4	EnzymesIBA 01/2021 - 08/2005
4	Bendamustine Hydrochloride FDA Link 02/2020 - 09/2011
4	Arsenic Trioxide (Trisenox)FDA Link 11/2019 - 02/2009
4	Peptides (Polypeptides)IBA 01/2014 - 08/2005
4	Alemtuzumab (Campath)FDA Link 08/2013 - 09/2006
4	CCAAT-Enhancer-Binding Protein-alphaIBA 02/2011 - 02/2004
4	Imatinib Mesylate (Gleevec)FDA Link 11/2007 - 12/2006
4	Hyaluronic Acid (Hyaluronan)IBA 06/2007 - 09/2002
3	enasidenibIBA 06/2022 - 01/2021
3	obinutuzumabIBA 01/2022 - 03/2014
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 08/2010
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 02/2006
3	Phosphotransferases (Kinase)IBA 01/2022 - 03/2013
3	ivosidenibIBA 01/2022 - 01/2021
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 05/2008
3	Gemtuzumab (Mylotarg)FDA Link 11/2021 - 01/2016
3	Valproic Acid (Depakote)FDA LinkGeneric 01/2020 - 06/2014
3	Protein Isoforms (Isoforms)IBA 01/2020 - 03/2013
3	Dasatinib (BMS 354825)FDA Link 01/2018 - 10/2008
3	Chlorambucil (Leukeran)FDA Link 06/2014 - 10/2009
3	NF-kappa B (NF-kB)IBA 04/2013 - 11/2002
2	Immunomodulating AgentsIBA 01/2022 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
2	ibrutinibIBA 01/2022 - 01/2018
2	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2021 - 01/2021
2	BI 6727IBA 08/2021 - 08/2014
2	Circular RNAIBA 01/2021 - 12/2017
2	Monoclonal AntibodiesIBA 01/2021 - 02/2006
2	fms-Like Tyrosine Kinase 3IBA 10/2020 - 01/2020
2	Thymidine KinaseIBA 01/2020 - 01/2018
2	Histone Deacetylase InhibitorsIBA 01/2020 - 07/2016
2	CytokinesIBA 01/2019 - 07/2004
2	Insulin-Like PeptidesIBA 01/2019 - 09/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 01/2014
2	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2016 - 06/2013
2	Sunitinib (Sutent)FDA Link 06/2015 - 02/2005
2	Granzymes (Granzyme)IBA 01/2014 - 06/2007

Therapy/Procedure

52	Therapeutics 10/2022 - 09/2002
36	Drug Therapy (Chemotherapy) 01/2022 - 08/2002
27	Stem Cell Transplantation 01/2019 - 04/2002
11	Immunotherapy 04/2020 - 09/2002
9	Hematopoietic Stem Cell Transplantation 01/2022 - 12/2006
5	Induction Chemotherapy 01/2022 - 11/2005
4	Cell Transplantation 01/2022 - 02/2008
4	Transplantation 01/2020 - 01/2016
4	Salvage Therapy 11/2019 - 02/2009
2	Aftercare (After-Treatment) 01/2020 - 01/2016